作者
C. Matthias Wilk,Flurin Cathomas,Orsolya Török,Jessica Le Bérichel,Matthew D. Park,Camille Bigenwald,George R. Heaton,Pauline Hamon,Leanna Troncoso,Brooks Scull,Diana K. Dangoor,Aymeric Silvin,Ryan Fleischmann,Meriem Belabed,Howard Lin,Elias Merad Taouli,Steffen Boettcher,Long Li,Antonio Aubry,Markus G. Manz,Julia Kofler,Zhenyu Yue,Sérgio A. Lira,Florent Ginhoux,John F. Crary,Kenneth L. McClain,Jennifer Picarsic,Scott J. Russo,Carl E. Allen,Miriam Mérad
摘要
Neurodegenerative diseases (ND) are characterized by progressive loss of neuronal function. Mechanisms of ND pathogenesis are incompletely understood, hampering the development of effective therapies. Langerhans cell histiocytosis (LCH) is an inflammatory neoplastic disorder caused by hematopoietic progenitors expressing mitogen-activated protein kinase (MAPK)-activating mutations that differentiate into senescent myeloid cells that drive lesion formation. Some individuals with LCH subsequently develop progressive and incurable neurodegeneration (LCH-ND). Here, we showed that LCH-ND was caused by myeloid cells that were clonal with peripheral LCH cells. Circulating BRAFV600E+ myeloid cells caused the breakdown of the blood-brain barrier (BBB), enhancing migration into the brain parenchyma where they differentiated into senescent, inflammatory CD11a+ macrophages that accumulated in the brainstem and cerebellum. Blocking MAPK activity and senescence programs reduced peripheral inflammation, brain parenchymal infiltration, neuroinflammation, neuronal damage and improved neurological outcome in preclinical LCH-ND. MAPK activation and senescence programs in circulating myeloid cells represent targetable mechanisms of LCH-ND.